Cargando…
Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress
BACKGROUND: FGF21 is a promising intervention therapy for metabolic diseases as fatty liver, obesity and diabetes. Recent results suggest that FGF21 is highly expressed in hepatocytes under metabolic stress caused by starvation, hepatosteatosis, obesity and diabetes. Hepatic FGF21 elicits metabolic...
Autores principales: | Yang, Chaofeng, Lu, Weiqin, Lin, Tao, You, Pan, Ye, Min, Huang, Yanqing, Jiang, Xianhan, Wang, Cong, Wang, Fen, Lee, Mong-Hong, Yeung, Sai-Ching J, Johnson, Randy L, Wei, Chongjuan, Tsai, Robert Y, Frazier, Marsha L, McKeehan, Wallace L, Luo, Yongde |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637159/ https://www.ncbi.nlm.nih.gov/pubmed/23590285 http://dx.doi.org/10.1186/1471-230X-13-67 |
Ejemplares similares
-
Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012) -
Stressed Liver and Muscle Call on Adipocytes with FGF21
por: Luo, Yongde, et al.
Publicado: (2013) -
Roles of endocrine FGF signaling in metabolic health and cancer
por: Luo, Yongde, et al.
Publicado: (2014) -
Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations
por: Luo, Yongde, et al.
Publicado: (2013) -
Overexpression of FGF9 in Prostate Epithelial Cells Augments Reactive Stroma Formation and Promotes Prostate Cancer Progression
por: Huang, Yanqing, et al.
Publicado: (2015)